Please assess the completion status of the following clinical trial:

Trial Title: Tricyclic Antidepressants (TCAs) on Gastric Emptying

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sixty normal subjects, males and females within the ages of 18 to 65 years, will be studied. Normal control subjects will be recruited for voluntary participation through poster advertisements. A normal subject is defined as a person with no gastrointestinal (GI) symptoms; no prior history of peptic ulcer disease or irritable bowel disease; no previous history of a GI motility disorder (including, but not limited to, achalasia, gastroparesis); on no medications for GI disorders; no history of prior surgery on the GI tract (esophagus, stomach, large or small intestine); and a normal physical examination.~Exclusion Criteria:~* History of a motility disorder (including, but not limited to, achalasia, gastroparesis)~* History of peptic ulcer disease~* Symptoms referable to gastric dysmotility (nausea, vomiting, early satiety, heartburn, postprandial abdominal distension)~* Use of medications that may affect GI motor function (beta adrenergic receptor blockers, calcium channel blockers, histamine type 2 receptor antagonists, proton pump inhibitors, prokinetic agents, antidepressants, and the use of narcotic analgesics)~* Regular use of nonsteroidal anti-inflammatory medications~* Use of monoamine oxidase inhibitors~* Pregnancy or breast feeding~* Prior gastrointestinal surgery (except appendectomy)~* Contraindications to amitriptyline or desipramine, which will be exclusion criteria to the study, include hypersensitivity or allergy to any tricyclic drug, concomitant therapy with a monoamine oxidase inhibitor, recent myocardial infarction, myelography within previous 48 hours, or lactation. In addition, history of prostate problems, history of urinary retention, known glaucoma, history of seizures, or thyroid or liver dysfunction are exclusionary criteria to the use of TCAs and to entry into this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: t

Study Arms:
- Nortriptyline (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).